Telehealth company Hims & Hers Health (NYSE: HIMS) announced better-than-expected revenue in Q2 CY2026, with sales up 38.2% year on year to $753.2 million. On top of that, next quarter’s revenue guidance ($890 million at the midpoint) was surprisingly good and 12.4% above what analysts were expecting. Its non-GAAP loss of $0.09 per share was significantly below analysts’ consensus estimates.

Is now the time to buy HIMS? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Hims & Hers Health’s second quarter results were driven by strong subscriber growth and a ramp-up in its branded weight loss offerings, yet the market reacted negatively, with shares declining over 5%. Management pointed to accelerated customer acquisition, particularly from new launches in AI-powered services and expanded product categories. CEO Andrew Dudum stressed that the company’s “investment in AI and technology is delivering a health experience that we believe no other company can replicate.” The quarter also included significant investments in infrastructure, entry into new specialties like testosterone therapy, and the largest acquisition in company history, Eucalyptus. However, rising operating expenses and ongoing litigation-related costs were highlighted as key pressures.

Looking ahead, Hims & Hers Health is prioritizing further investment in AI capabilities, international market penetration, and broader product assortment as central to its elevated guidance. Management expects continued efficiencies from AI to lower customer support costs and improve retention, with CTO Mo ElShenawy stating, “We are making AI load-bearing, not decorative,” and forecasting that these investments will “pay for itself in short order.” The company aims to leverage its global platform and deepen its partnerships, particularly in the weight loss and peptide therapy categories, while preparing for regulatory developments that could unlock new offerings. Strategic flexibility remains a focus, as Hims & Hers plans to reinvest efficiency gains into enhanced consumer experiences and international growth.

Key Insights from Management’s Remarks

Management attributed the quarter’s outperformance to rapid customer growth, AI-led engagement, and successful integration of new specialties and international markets.

• AI-driven engagement: The initial rollout of the AI-native experience for Hers weight loss customers led to a threefold increase in customer engagement, with AI handling 80% of inquiries and reducing nonclinical support tasks by nearly 50%. Management expects to expand this model across all segments, aiming for improved retention and operational efficiency.

• Testosterone therapy momentum: Hims’ testosterone offering scaled more rapidly than any specialty outside weight loss, supported by at-home diagnostics and ongoing provider-guided treatment. This success has encouraged management to plan launches of injectable and oral testosterone options and to extend the model to other complex categories, such as peptide therapy, depending on regulatory approvals.

• Eucalyptus acquisition impact: The June acquisition of Eucalyptus, a leading digital health provider in Australia, the U.K., and Germany, expanded Hims & Hers’ international footprint. These markets now each generate over $100 million in annualized revenue, diversifying the company’s revenue base and accelerating growth opportunities abroad.

• Cross-sell and data leverage: Management highlighted that large audience specialties, notably weight loss and sexual health, serve as gateways to cross-sell additional services. The expanding subscriber base enriches the company’s proprietary data, allowing for better treatment matching and customized subscriber tools, which are expected to drive both future revenue and platform improvements.

• Operational efficiencies and partnerships: AI initiatives and supply chain scale have begun to deliver cost savings, particularly in marketing and customer support. Strategic partnerships, especially with pharmaceutical firms like Novo Nordisk, have also generated marketing tailwinds and facilitated access to high-demand therapies, further strengthening the company’s market position.

Drivers of Future Performance

Hims & Hers Health’s outlook centers on scaling its AI capabilities, expanding its international presence, and deepening its specialty offerings to drive revenue growth and margin improvements.

• AI investment and payback: Management is accelerating investment in AI with the expectation of a 12- to 18-month payback. These initiatives are already reducing cancellations, improving engagement, and enabling lower pricing, which should expand the addressable market and support higher lifetime value per subscriber.

• International scale-up: The company intends to allocate efficiency gains toward aggressive investment in international markets such as the U.K., Germany, Australia, and Canada, where adoption of digital health and weight loss solutions is still developing. Management believes these markets will evolve into meaningful profit centers as scale is achieved.

• New category launches and regulatory risk: Hims & Hers is preparing to launch new products in peptide therapies and advanced hormonal treatments, contingent on regulatory clarity. Management cites ongoing FDA processes as a gating factor and underscores the need for robust clinical protocols and supply chain validation before full commercial rollout.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will be watching (1) whether AI-enabled engagement and retention rates improve across all customer segments, (2) the pace and profitability of international expansion following the Eucalyptus acquisition, and (3) the regulatory progress on peptide therapies and advanced hormonal treatments. The effectiveness of cross-sell strategies and the integration of new specialties into the global platform will also be key areas for ongoing analysis.

Hims & Hers Health currently trades at $30.54, down from $32.10 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.